



Fig. 1**A.****B.**


Fig. 2


Fig. 3


Fig. 4


Fig. 5


Fig. 6


Fig. 7


Fig. 8


Fig. 9


Fig. 10


Fig. 11


Fig. 12


Fig. 13



Fig. 14

Fig. 15

Signal peptide is displayed in **bolded and underlined text** (not present in the mature protein): **SEQ ID NO: 12**
 TRAIL receptor binding domain monomer modules in plain text: as 120-281 and 121-281 of SEQ ID NO:1,
 respectively

linkers between the TRAIL monomers in bolded text: **SEQ ID NO:2**

Fc-domain of human IgG1 in *italicized and underlined text*: *SEQ ID NO: 10*

Hinge-linker between the scTRAIL –RBD and Fc is displayed in ***bolded and italicized text***: ***SEQ ID NO: 11***

METDTLLVFVLLVWVPAGNGQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGH
 SFLSNLHLRNGELVIHEKGFYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYDPDPIILLM
 KSARNSCWSDAEYGLYSIQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVGG***SGGS***
GNGSRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHFLSNLHLRNGELVIHE
 KGFYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYDPDPIILLKSARNSCWSDAEYGLY
 SIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVGG***SGSGNGS***RVAAHITGTRGRS
 NTLSSPNSKNEKALGRKINSWESSRSGHFLSNLHLRNGELVIHEKGFYIYSQTYFRFQEE
 IKENTKNDKQMVQYIYKYTSYDPDPIILLKSARNSCWSDAEYGLYSIQGGIFELKENDRIE
 VSVTNEHLIDMDHEASFFGAFLVGG***GPSSSSSSSGCDKTHTCPPC****PAPELLGGPSVFLFPP*
KPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYSSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSQVMHEA
*LHNHYTQKSLSLSPGK**

Fig. 17A




Fig. 17B





Fig. 18

Fig. 19





Fig. 20

22/25

Fig. 21

Treatment regimens shown refer to amounts of
TRAIL receptor agonist protein

**Fig. 22**

Treatment regimens shown refer to amounts of
TRAIL receptor agonist protein





Fig. 23

Treatment regimens shown refer to amounts of
TRAIL receptor agonist protein






Fig. 24




Fig. 24